Alison returned to CHERE in May 2016 as a Chancellor’s Postdoctoral Research Fellow. After completing her PhD on the costs of chemotherapy side effects at CHERE in 2013, she did a postdoctoral fellowship at the National Cancer Registry in Ireland. There, she worked on the costs of cancer survivorship, including lost productivity and patient preferences for cancer follow-up services. Prior to her PhD, Alison worked in cancer research at the National Breast and Ovarian Cancer Centre (now Cancer Australia) and the NHMRC Clinical Trials Centre at the University of Sydney.
Alison’s current work examines some of the societal costs of cancer. This includes estimating cancer related productivity losses in Australia, and exploring the differences between how individuals and society make trade-offs between the outcomes of cancer treatment (such as survival) and quality of life.
More broadly, Alison’s research interests are centred around using health economics and health services research to improve cancer care by providing relevant and reliable information for decision making. She also has keen interests in early career researcher development, communicating research to the public, and the use of social media in academia.
- 2015 - MASCC Young Investigator of the Year Award "Comparing the costs of three prostate cancer follow-up strategies: A cost minimiation analysis"
- 2015 - HESG Best Poster Presentation Award "Cognitive interviewing highlights unanticipated decision making in a discrete choice experiment"
- 2015 - ISPOR Best New Investigator Podium Presentation Award "The burden of cancer in emerging economies: productivity loss as an alternative perspective"
- ANZ Health Services Research Association
- Australian Health Economics Association
- Health Economics Study Group (UK)
- International Health Economics Association
- International Society for Pharmacoeconomics and Outcomes Research
I am a health economist and health services researcher specialising in the economics of cancer care. My current work examines the productivity losses resulting from cancer, and how patients trade-off between quality of life and survival when choosing treatments. I am also passionate about early career researcher development and science communications.
Health economics, Evidence based practice, Clinical trials methodology, Research methods
Pearce, A.M., Sharp, L., Hanly, P., Barchuk, A., Bray, F., de Camargo Cancela, M., Gupta, P., Meheus, F., Qiao, Y.L., Sitas, F., Wang, S.M. & Soerjomataram, I. 2018, 'Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China, and South Africa (BRICS): A population-based comparison', Cancer Epidemiology, vol. 53, pp. 27-34.View/Download from: Publisher's site
Hanly, P., Pearce, A. & Sharp, L. 2017, 'Cancer and productivity loss in the Irish economy: an employer's perspective', The Irish Journal of Management, vol. 36, no. 1, pp. 5-20.View/Download from: Publisher's site
Pearce, A.M., Haas, M., Viney, R., Pearson, S.-.A., Haywood, P., Brown, C. & Ward, R. 2017, 'Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study', PLoS ONE, vol. 12, no. 10.View/Download from: UTS OPUS or Publisher's site
Thomas, A.A., Pearce, A., O'Neill, C., Molcho, M. & Sharp, L. 2017, 'Urban–rural differences in cancer-directed surgery and survival of patients with non-small cell lung cancer', Journal of Epidemiology and Community Health, vol. 71, no. 5, pp. 468-474.View/Download from: Publisher's site
Thomas, A.A., Pearce, A., Sharp, L., Gardiner, R.A., Chambers, S., Aitken, J., Molcho, M. & Baade, P. 2017, 'Socioeconomic disadvantage but not remoteness affects short-term survival in prostate cancer: A population-based study using competing risks', Asia-Pacific Journal of Clinical Oncology, vol. 13, no. 2, pp. e31-e40.View/Download from: Publisher's site
Pearce, A., Bradley, C., Hanly, P., O'Neill, C., Thomas, A.A., Molcho, M. & Sharp, L. 2016, 'Projecting productivity losses for cancer-related mortality 2011 - 2030.', BMC Cancer, vol. 16, no. 1, pp. 1-10.View/Download from: UTS OPUS or Publisher's site
BACKGROUND: When individuals stop working due to cancer this represents a loss to society - the loss of productivity. The aim of this analysis was to estimate productivity losses associated with premature mortality from all adult cancers and from the 20 highest mortality adult cancers in Ireland in 2011, and project these losses until 2030. METHODS: An incidence-based method was used to estimate the cost of cancer deaths between 2011 and 2030 using the Human Capital Approach. National data were used for cancer, population and economic inputs. Both paid work and unpaid household activities were included. Sensitivity analyses estimated the impact of assumptions around future cancer mortality rates, retirement ages, value of unpaid work, wage growth and discounting. RESULTS: The 233,000 projected deaths from all invasive cancers in Ireland between 2011 and 2030 will result in lost productivity valued at €73 billion; €13 billion in paid work and €60 billion in household activities. These losses represent approximately 1.4 % of Ireland's GDP annually. The most costly cancers are lung (€14.4 billion), colorectal and breast cancer (€8.3 billion each). However, when viewed as productivity losses per cancer death, testis (€364,000 per death), cervix (€155,000 per death) and brain cancer (€136,000 per death) are most costly because they affect working age individuals. An annual 1 % reduction in mortality reduces productivity losses due to all invasive cancers by €8.5 billion over 20 years. CONCLUSIONS: Society incurs substantial losses in productivity as a result of cancer-related mortality, particularly when household production is included. These estimates provide valuable evidence to inform resource allocation decisions in cancer prevention and control.
Pearce, A.M., Ryan, F., Drummond, F.J., Thomas, A.A., Timmons, A. & Sharp, L. 2016, 'Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis', SUPPORTIVE CARE IN CANCER, vol. 24, no. 2, pp. 879-886.View/Download from: Publisher's site
Norman, R., Mulhern, B., Viney, R., Bansback, N. & Pearce, A. 2016, 'The Impact of Duration on EQ5D5L Value Sets Derived from a Discrete Choice Experiment', Value in Health, vol. 19, no. 7, pp. A828-A828.
Hanly, P., Pearce, A. & Sharp, L. 2015, 'Cancer And Premature Mortality In Ireland: An Employer's Perspective Following The Friction Cost Approach.', Value in Health, vol. 18, no. 7, pp. A465-A465.View/Download from: UTS OPUS or Publisher's site
Pearce, A., Haas, M., Viney, R., Haywood, P., Pearson, S.-.A., van Gool, K., Srasuebkul, P. & Ward, R. 2015, 'Can administrative data be used to measure chemotherapy side effects?', Expert review of pharmacoeconomics & outcomes research, vol. 15, no. 2, pp. 215-222.View/Download from: Publisher's site
Many of the issues with using data from clinical trials and observational studies for economic evaluations are highlighted in the case of chemotherapy side effects. We present the results of an observational cohort study using linked administrative data. The chemotherapy side effects identified in the administrative data are compared with patient self-reports of such events. The results of these comparisons are then used to guide a discussion of the issues surrounding the use of administrative data to identify clinical events for the population of economic models. Although the advantages of easy access and generalizability of the results make administrative data an attractive option for populating economic models, this is not always possible because of the limitations of these data.
Pearce, A., Timmons, A., O'Sullivan, E., Gallagher, P., Gooberman-Hill, R., Thomas, A.A., Molcho, M., Butow, P. & Sharp, L. 2015, 'Long-term workforce participation patterns following head and neck cancer.', Journal of Cancer Survivorship, vol. 9, no. 1, pp. 30-39.View/Download from: UTS OPUS or Publisher's site
PURPOSE: This analysis describes the long-term workforce participation patterns of individuals diagnosed with head and neck cancer (HNC). METHODS: Survivors of HNC (ICD10 C00-C14, C32) diagnosed at least 8 months previously were identified from the National Cancer Registry Ireland and sent a survey including questions about working arrangements before and since diagnosis. Descriptive statistics and multivariate logistic regression were used to examine the factors that influence workforce participation at 0, 1 and 5 years after diagnosis. RESULTS: Two hundred sixty-four individuals employed at the time of diagnosis responded to the survey, an average 6 years post-diagnosis. Seventy-seven percent took time off work after diagnosis, with a mean work absence of 9 months (range 0-65 months). Fifty-two percent of participants reduced their working hours (mean reduction 15 h/week). The odds of workforce participation following HNC were increased by not being eligible for free medical care (OR 2.61, 95% CI 1.15-5.94), having lip, mouth or salivary gland cancer (compared to cancer of the pharynx or cancer of the larynx, OR 2.79, 1.20-6.46), being self-employed (OR 2.01, 1.07-3.80), having private health insurance (OR 2.06, 1.11-3.85) and not receiving chemotherapy (OR 2.82, 1.31-6.06). After 5 years, only the effect of medical card remained (i.e., medical insurance) (OR 4.03, 1.69-9.62). CONCLUSIONS: Workforce participation patterns after HNC are complex and are influenced by cancer, treatment and employment factors. IMPLICATIONS FOR CANCER SURVIVORS: Patients should be informed of the potential impacts of HNC on workforce participation, and clinicians, policy makers and employers should be aware of these potential longer-term effects and related variables.
Pearce, A.M., Hanly, P., Timmons, A., Walsh, P.M., O'Neill, C., O'Sullivan, E., Gooberman-Hill, R., Thomas, A.A., Gallagher, P. & Sharp, L. 2015, 'Productivity Losses Associated with Head and Neck Cancer Using the Human Capital and Friction Cost Approaches.', Applied health economics and health policy, vol. 13, no. 4, pp. 359-367.View/Download from: Publisher's site
Previous studies suggest that productivity losses associated with head and neck cancer (HNC) are higher than in other cancers. These studies have only assessed a single aspect of productivity loss, such as temporary absenteeism or premature mortality, and have only used the Human Capital Approach (HCA). The Friction Cost Approach (FCA) is increasingly recommended, although has not previously been used to assess lost production from HNC. The aim of this study was to estimate the lost productivity associated with HNC due to different types of absenteeism and premature mortality, using both the HCA and FCA.Survey data on employment status were collected from 251 HNC survivors in Ireland and combined with population-level survival estimates and national wage data. The cost of temporary and permanent time off work, reduced working hours and premature mortality using both the HCA and FCA were calculated.Estimated total productivity losses per employed person of working age were EUR253,800 using HCA and EUR6800 using FCA. The main driver of HCA costs was premature mortality (38% of total) while for FCA it was temporary time off (73% of total).The productivity losses associated with head and neck cancer are substantial, and return to work assistance could form an important part of rehabilitation. Use of both the HCA and FCA approaches allowed different drivers of productivity losses to be identified, due to the different assumptions of the two methods. For future estimates of productivity losses, the use of both approaches may be pragmatic.
Thomas, A.A., Gallagher, P., O'Ceilleachair, A., Pearce, A., Sharp, L. & Molcho, M. 2015, 'Distance from treating hospital and colorectal cancer survivors' quality of life: a gendered analysis', SUPPORTIVE CARE IN CANCER, vol. 23, no. 3, pp. 741-751.View/Download from: Publisher's site
Hanly, P., Pearce, A. & Sharp, L. 2014, 'The cost of premature cancer-related mortality: a review and assessment of the evidence', Expert Review of Pharmacoeconomics and Outcomes Research, vol. 14, no. 3, pp. 355-377.View/Download from: UTS OPUS or Publisher's site
Worldwide, 8.2 million people die of cancer annually. Cancer has a significant societal impact, impinging on countries' economic health. We reviewed methodological aspects, and the main cost results, of studies calculating premature mortality losses from cancer published 2000–2013 and identified gaps in the evidence-base. Thirty-one studies were identified (Europe, 17; USA, 11; Korea, 2; Puerto Rico, (1). The human capital approach dominated (30 studies); studies differed in how they implemented the methodological approach. Aspects of methodology were poorly reported. Premature cancer-related mortality costs are substantial and appear to be rising. The evidence-base has gaps in relation to cancer sites studied and less developed and emerging economies. Comprehensive, standardised, estimates of premature mortality losses are needed if these measures are to be useful in assessing the societal cancer burden.
Noushi, F., Spillane, A.J., Uren, R.F., Cooper, R., Allwright, S., Snook, K.L., Gillet, D., Pearce, A.M. & Gebski, V. 2014, 'High discordance rates between sub-areolar and peri-tumoural breast lymphoscintigraphy (vol 39, pg 1053, 2013)', EJSO, vol. 40, no. 2, pp. 246-246.View/Download from: Publisher's site
Pearce, A.M., Haas, M., Viney, R., Ward, R., Haywood, P. & Investigators, E. 2014, 'RATES OF CHEMOTHERAPY ADVERSE-EVENTS IN CLINICAL PRACTICE: RESULTS FROM PROSPECTIVE COHORT STUDY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol. 10, pp. 43-44.
Pearce, A.M., Van Gool, K., Haywood, P. & Haas, M.R. 2014, 'Delays in access to affordable medicines: putting policy into perspective - Authors' response', Australian Health Review, vol. 38, no. 1, pp. 16-17.
Sharp, L., Deady, S., Gallagher, P., Molcho, M., Pearce, A., Alforque Thomas, A., Timmons, A. & Comber, H. 2014, 'The magnitude and characteristics of the population of cancer survivors: using population-based estimates of cancer prevalence to inform service planning for survivorship care', BMC Cancer, vol. 14, no. 1, pp. 1-10.View/Download from: UTS OPUS or Publisher's site
Rising cancer incidence and survival mean that the number of cancer survivors is growing. Accumulating evidence suggests many survivors have long-term medical and supportive care needs, and that these needs vary by survivors' socio-demographic and clinical characteristics. To illustrate how cancer registry data may be useful in survivorship care service planning, we generated population-based estimates of cancer prevalence in Ireland and described socio-demographic and clinical characteristics of the survivor population.
Details of people diagnosed with invasive cancer (ICD10 C00-C96) during 1994–2011, and who were still alive on 31/12/2011, were abstracted from the National Cancer Registry, and tabulated by cancer site, sex, current age, marital status, initial treatment, and time since diagnosis. Associations were investigated using chi-square tests.
After excluding non-melanoma skin cancers, 17-year cancer prevalence in Ireland was 112,610 (females: 58,054 (52%) males: 54,556 (48%)). The four most prevalent cancers among females were breast (26,066), colorectum (6,598), melanoma (4,593) and uterus (3,505) and among males were prostate (23,966), colorectum (8,207), lymphoma (3,236) and melanoma (2,774). At the end of 2011, 39% of female survivors were aged <60 and 35% were 70 compared to 25% and 46% of males (p < 0.001). More than half of survivors of bladder, colorectal and prostate cancer were 70. Cancers with the highest percentages of younger (<40) survivors were: testis (50%); leukaemia (females: 28%; males: 22%); cervix (20%); and lymphoma (females: 19%; males: 20%). Fewer female (57%) than male (64%) survivors were married but the percentage single was similar (17-18%). More female (25%) than male survivors (18%; p <0.001) were 10 years from diagnosis. Overall, 69% of survivors had undergone cancer-directed surgery, and 39%, 32% and 18% had received radiotherapy, chemotherapy and hormone therapy, respectively. These frequ...
Thomas, A.A., Timmons, A., Molcho, M., Pearce, A., Gallagher, P., Butow, P., O'Sullivan, E., Gooberman-Hill, R., O'Neill, C. & Sharp, L. 2014, 'Quality of life in urban and rural settings: a study of head and neck cancer survivors.', Oral Oncology, vol. 50, no. 7, pp. 676-682.View/Download from: UTS OPUS or Publisher's site
OBJECTIVE: Urban-rural variation in cancer incidence, treatment, and clinical outcomes has been well researched. With the growing numbers and longer lifespan of cancer survivors, quality of life (QOL) is now a critical issue. The present study investigates the QOL of head and neck cancer (HNC) survivors in Ireland, paying special attention to urban and rural variation. METHODS: From the population-based National Cancer Registry Ireland, we identified 991 survivors of HNC (ICD10 C00-C14, C32), who were at least eight months post-diagnosis, and invited them to complete a postal survey. We used self-reported data and information from the Registry to create a composite variable classifying respondents' current area of residence as "urban" or "rural." Respondents self-reported QOL using the Functional Assessment for Cancer Therapy with Head and Neck module (FACT-HN). We used bootstrap linear regression to control for confounding variables, while estimating the association of urban and rural residence to FACT-HN domain scores. RESULTS: We obtained survey and Registry data from 583 HNC survivors. Controlling for demographic and clinical variables, rural survivors reported higher physical (coefficient 1.27, bias-corrected and accelerated 95% confidence interval 0.54, 2.43), emotional (coef. 0.99, 95% CI 0.21, 2.02), and HNC-specific (coef. 1.55, 95% CI 0.32, 3.54) QOL than their urban counterparts. Social and functional QOL did not differ significantly. CONCLUSIONS: These findings add to growing evidence of important differences in life experiences of cancers survivors in urban and rural settings. Results such as these will allow health professionals, policy makers and service providers to better serve these populations.
Noushi, F., Spillane, A., Uren, R.F., Cooper, R., Allwright, S., Snook, K.L., Gillet, D., Pearce, A.M. & Gebski, V. 2013, 'High discordance rates between sub-areolar and peri-tumoural breast lymphoscintigraphy', European Journal of Surgical Oncology, vol. 39, no. 10, pp. 1053-1060.View/Download from: UTS OPUS or Publisher's site
Objective To test the hypothesis that sub-areolar (SA) lymphoscintigraphy (LSG) identifies the same sentinel node as peri-tumoural (PT) injections. Background It is commonly believed that all LSG techniques will identify the same sentinel lymph nodes (SLN) draining the breast. Hybrid imaging technology (SPECT/CT) allows accurate identification of the exact location of SLNs. Using SPECT/CT SA and PT LSG techniques were compared. Method In a multi-centre trial 39 patients sequentially underwent LSG (SA followed by PT) separated by 27 days. Patients were referred by 4 surgeons to 3 LSG centres, with standardization of isotope (99mTc-antimony sulfide colloid), LSG and SPECT/CT evaluation techniques. LSG were evaluated for SLN concordance and degree of discordance in the axilla and internal mammary nodes (IMN). Results 39 eligible patients, median age 62 years, were recruited. Successful axillary SLN mapping for SA and PT injection techniques was 87% and 95% respectively. Successful internal mammary SLN mapping occurred with SA and PT LSG in 5% and 36% respectively. Discordance was identified in the IMN (39%) and axilla (21%), with an overall rate of discordance between SA and PT LSG of 56%.
Pearce, A.M., Haas, M. & Viney, R. 2013, 'AUSTRALIAN STANDARD COSTS AND CONSEQUENCES OF FOUR CHEMOTHERAPY ADVERSE EVENTS', VALUE IN HEALTH, vol. 16, no. 7, pp. A404-A404.
Pearce, A.M., Haas, M. & Viney, R. 2013, 'CAN ADMINISTRATIVE DATA PREDICT CHEMOTHERAPY ADVERSE EVENTS?', VALUE IN HEALTH, vol. 16, no. 7, pp. A392-A392.
Pearce, A.M., Haas, M.R. & Viney, R.C. 2013, 'Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review', Applied Health Economics and Health Policy, vol. 11, no. 6, pp. 619-637.View/Download from: UTS OPUS or Publisher's site
Background Antineoplastic drugs for cancer are often associated with adverse events, which influence patients' physical health, quality of life and survival. However, the modelling of adverse events in cost-effectiveness analyses of antineoplastic drugs has not been examined. Aims This article reviews published economic evaluations that include a calculated cost for adverse events of antineoplastic drugs. The aim is to identify how existing models manage four issues specific to antineoplastic drug adverse events: the selection of adverse events for inclusion in models, the influence of dose modifications on drug quantity and survival outcomes, the influence of adverse events on quality of life and the consideration of multiple simultaneous or recurring adverse events. Methods A systematic literature search was conducted using MESH headings and key words in multiple electronic databases, covering the years 19992009. Inclusion criteria for eligibility were papers covering a population of adults with solid tumour cancers, the inclusion of at least one adverse event and the resource use and/or costs of adverse event treatment. Results From 4,985 citations, 26 eligible articles were identified. Studies were generally of moderate quality and addressed a range of cancers and treatment types. While the four issues specific to antineoplastic drug adverse events were addressed by some studies, no study addressed all of the issues in the same model. Conclusion This review indicates that current modelling assumptions may restrict our understanding of the true impact of adverse events on cost effectiveness of antineoplastic drugs. This understanding could be improved through consideration of the selection of adverse events, dose modifications, multiple events and quality of life in cost-effectiveness studies.
Pearce, A.M., Timmons, A., Hanly, P., O'Neill, C. & Sharp, L. 2013, 'WORKFORCE PARTICIPATION AND PRODUCTIVITY LOSSES AFTER HEAD AND NECK CANCER', VALUE IN HEALTH, vol. 16, no. 7, pp. A418-A418.
Pearce, A.M., Smead, J.M. & Cameron, I.D. 2012, 'Retrospective cohort study of accident outcomes for individuals who have successfully undergone driver assessment following stroke', AUSTRALIAN OCCUPATIONAL THERAPY JOURNAL, vol. 59, no. 1, pp. 56-62.View/Download from: UTS OPUS or Publisher's site
Pearce, A.M., Van Gool, K., Haywood, P. & Haas, M.R. 2012, 'Delays in access to affordable medicines: putting policy into perspective', Australian Health Review, vol. 36, no. 4, pp. 412-418.View/Download from: UTS OPUS or Publisher's site
To save costs, the Australian Government recently deferred approval of seven new medicines recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) for up to 7 months.Objectives: The aim of this research is to examine the timelines of PBAC applications following approval by the Therapeutic Goods Administration (TGA), allowing the recent Cabinet delays to be considered in the context of the overall medicines approval process. Methods. All new chemical entities and products for new indications approved in 2004 by the Australian Drug Evaluation Committee (ADEC) were identified. Outcomes of PBAC meetings from 2004 to 2010 were then searched to identify if and when these products were reviewed by PBAC. Results: ADEC recommended 63 eligible products for registration in 2004. Of the 113 submissions made to PBAC for these products, 66 were successful. Only 43% of the products were submitted to PBAC within 2 years, with an average 17-month delay from TGA approval of a product to consideration by the PBAC. Conclusions: Cabinet decisions to defer listing of new medicines delays access to new treatments. This occurred in addition to other longer delays, earlier in the approval process for medicines, resulting in a significant impact on the overall timeliness of listing.
Pearce, A.M., Haas, M., van Gool, K. & Investigators, E. 2010, 'THE COST OF CHEMOTHERAPY SIDE EFFECTS', VALUE IN HEALTH, vol. 13, no. 7, pp. A515-A515.
Pearce, A., Shaw, J., Lopez, A. & Price, M. 2017, 'Does comorbid anxiety in-crease health resource use or costs among cancer patents? A re-view of the evidence', Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting, Sydney.
Pearce, A.M. 2017, 'Social media as a strategy for career development [Conference Presentation]', Australian Health Economics Doctoral Workshop, Sydney.
Tomalin, A., Pearce, A.M., Kaambwa, B., Horevoorts, N., Duijts, S., Mols, F., van de Pol, L. & Koczwara, B. 2017, 'Financial toxicity, employment and quality of life of cancer survivors. A secondary analysis of the PROFILES registry', Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting, Sydney.
Pearce, A.M. 2016, 'Moving cancer follow-up into primary care: Exploring the tension between outcomes, costs and patient preferences', Screening and Test Evaluation Program (STEP), University of Sydney.
Pearce, A.M. 2016, 'Advances in Oncology: Can we afford the future? (Invited member of debate team)', Sydney Catalyst Education Dinner Series, Sydney.
Pearce, A.M. 2016, 'Moving cancer follow-up into primary care: Exploring the tension between outcomes, costs and patient preferences', Screening and Test Evaluation Program (STEP) Seminar, University of Sydney.
Pearce, A.M., Sharp, L., Gallagher, P., Timmons, A. & Watson, V. 2016, 'Cancer survivors find it difficult to think hypothetically about their future care in a DCE: a think aloud study', Australian Health Economics Society Conference, Perth.
Pearce, A.M., Sharp, L., Gallagher, P., Timmons, A. & Watson, V. 2016, 'Pre-testing with cognitive interviewing highlights unanticipated decision making in a DCE', International Academy of Health Preference Research, Singapore.
Pearce, A.M., Sharp, L., Gallagher, P., Timmons, A. & Watson, V. 2016, 'Pre-testing with cognitive interviewing highlights unanticipated decision making in a DCE', International Academy of Health Preference Research, Singapore.
Pearce, A.M., Hanly, P., Sharp, L. & Soerjomataram, I. 1970, 'The burden of cancer in emerging economies: Productivity loss a an alternative perspective', International Society of Pharmacoeconomics and Outcomes Research, Milan, Italy.
Pearce, A.M., Hanly, P., Sharp, L., Gupta, P. & Soerjomataram, I. 2015, 'Cancer-related productivity losses in emerging economies', International Association of Cancer Registries Conference, Mumbai, India.
Pearce, A.M., Ryan, F., Timmons, A., Thomas, A., Drummond, F. & Sharp, L. 2015, 'Comparing the costs of three prostate cancer follow-up strategies: A cost-minimisation analysis', MASCC/ISOO Annual Meeting on Supportive Care in Cancer, Copenhagen.
Pearce, A.M., Bradley, C., Hanly, P., O'Neill, C. & Sharp, L. 2014, 'Projecting productivity losses due to premature mortality from cancer 2010-2030', Irish Society for New Economists, Galway, Ireland.
Pearce, A.M., Haas, M., Viney, R., Pearson, S., Haywood, P. & Ward, R. 2014, 'Rates of chemotherapy adverse event in clinical practice: results from a prospective cohort study', World Cancer Congress, Melbourne.View/Download from: UTS OPUS
Pearce, A.M., Timmons, A., Hanly, P., O'Neill, C. & Sharp, L. 2014, 'Comparing the human capital and friction cost approaches to estimating productivity costs', International Health Economics Association Congress, Dublin, Ireland.